Business Wire

Thales to Provide Mobile Driver Licenses to State of Florida

13.10.2020 16:00:00 EEST | Business Wire | Press release

Share

The State of Florida will be the first state in the United States to provide mobile Driver Licenses with leading-edge security mechanisms, fully compliant with rigorous national and international standards. Thales will supply the Florida Department of Highway Safety and Motor Vehicles with mobile Driver License verification services, as well as a mobile Driver License solution for residents.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005021/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

In 2021, Florida residents will be able to apply for new mobile Driver Licenses that are easily accessible on a variety of devices, including smartphones and tablets. These mobile Driver Licenses meet the national and international standards from the American Association of Motor Vehicle Administrators and the International Organization for Standardization, meaning they can be used across the United States and internationally.

These new mobile Driver Licenses have the same validity as traditional driver’s licenses to verify identity, including proof of age and driving privileges. It also provides an additional role as a strong authentication tool, enabling Floridians to securely prove who they are online for a variety of services.

Now, to complement the traditional use of driver licenses to prove their identity, Florida residents will be able to simply activate their mobile identification application, select the type of verification needed, and hold up their mobile device. The mobile device never leaves the owners hand, making it a contact-free and convenient way to show ID.

“I’m excited for this innovation project that will make the state of Florida a national leader in offering secure and trusted mobile identification, which is a priority for our Governor, Ron DeSantis,” said Terry L. Rhodes, Executive Director of the Florida Department of Highway Safety and Motor Vehicles. “We have made a sustained commitment to the modernization of nearly every aspect of what our department does and how customers access our services, and Thales will be a great partner as Florida now steps into the future of mobile identification.”

“As ID fraud becomes more frequent and sophisticated, we made it a priority to reinforce ID verification by adding extra software security technologies. In the future, enterprises such as airports, hotels, car rental companies etc, in Florida will be able to rely on Thales to identify customers, while guaranteeing their privacy”, said Tony Lo Brutto, VP NORAM, Identity and Biometric Solutions at Thales.

These mobile Driver Licenses are harder to counterfeit, as they host a secure digitized credential whose authenticity can be checked rather than simply displaying a digital image of a driver license that could be easily manipulated.

For stronger privacy, users of mobile Driver Licenses control what information is displayed from the app depending on the context. For example, to enter a casino it only needs to show that the individual is old enough and the mobile Driver License will just display that information – not the individual’s name, date of birth, or address.

The Florida mobile Driver License program builds on Thales’ strong foundation of supporting state identity programs for 11 other U.S. states and five Canadian provinces.

Note to Editors

Thales, a leader in mobile driver’s license technology, successfully conducted the first U.S. mobile Driver’s License or Digital Driver’s License pilots across multiple states through a partnership and grant awarded in 2016 by the U.S. National Institute of Standards and Technology. Thales has recently been nationally recognized for the Digital ID Wallet, which incorporates the mobile Driver’s License solution, by Frost & Sullivan and ABI Research

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019.

Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT
Thales Group
Download HD pictures

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations

Digital Identity & Security
Vanessa Viala
+33 6 07 34 00 34
Vanessa.viala@thalesgroup.com

Thales, Media Relations
USA
Adam Kostecki
+1 (703) 838-5645
adam.kostecki@us.thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye